-
Mashup Score: 1Webprogram Unavailable - 1 day(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome - 10 day(s) ago
Key Points. Ivosidenib resulted in a CR rate of 38.9% and an ORR (CR+PR+mCR) of 83.3% in mIDH1 R/R MDS; median DoR was not reachedMedian OS in this R/R MDS
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Darko Medin - Biostatistician | Biostatistician, Darko Medin - 26 day(s) ago
Darko Medin is an experienced biostatistician offering consulting and education services for clinical research. Contact him now for expert statistical analysis.
Source: darkomedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
GI Oncology voices that stand out – as selected by peer survey – LARVOL / Aparna Parikh, cancer, Cathy Eng, Elizabeth Smyth, Ghassan Abou-Alfa, GI oncology,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Stephen V Liu: Results from phase III CONTACT-01 trial Journal of Clinical Oncology - OncoDaily - 1 month(s) ago
Stephen V Liu: Results from phase III CONTACT-01 trial Journal of Clinical Oncology / cancer, chemotherapy, immunotherapy, Journal of Clinical Oncology,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Toxic Positivity - 1 month(s) ago
If you google “toxic positivity definition,” a variety of resources and websites and memes and books pop up — it’s quite the subject. At a basic level, in my opinion, toxic …
Source: nohalfmeasures.blogCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Improved overall survival was achieved with nivolumab plus ipilimumab vs standard-of-care TKIs in patients with advanced hepatocellular carcinoma.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial - 1 month(s) ago
Nature Medicine – Results from a multicenter, randomized phase 2 trial in China show that adjuvant anti-PD-1 therapy in patients with resected hepatocellular carcinoma with microvascular invasion…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
RT @ManniMD1: 3) DSM XIII Mel 140 could not beat continuous len/dex in an older patient population. https://t.co/9NykX9rJkd